Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNLI NYSE:RCUS NASDAQ:SANA NASDAQ:TLX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$20.04+3.4%$19.72$12.58▼$23.77$3.18B0.991.75 million shs747,402 shsRCUSArcus Biosciences$24.20+0.3%$23.41$7.91▼$28.72$3.03B0.871.19 million shs216,640 shsSANASana Biotechnology$3.13+2.5%$3.24$1.99▼$6.55$869.66M2.173.04 million shs2.06 million shsTLXTelix Pharmaceuticals$9.70+1.3%$9.93$6.28▼$18.49$3.29B0.08216,466 shs57,991 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics+3.97%+7.12%-2.47%-13.06%+44.41%RCUSArcus Biosciences+2.96%+6.13%-4.83%+19.33%+167.22%SANASana Biotechnology-0.65%-0.33%-7.29%-26.86%+53.27%TLXTelix Pharmaceuticals+1.06%-5.90%-9.38%+40.94%-42.35%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNLIDenali Therapeutics$20.04+3.4%$19.72$12.58▼$23.77$3.18B0.991.75 million shs747,402 shsRCUSArcus Biosciences$24.20+0.3%$23.41$7.91▼$28.72$3.03B0.871.19 million shs216,640 shsSANASana Biotechnology$3.13+2.5%$3.24$1.99▼$6.55$869.66M2.173.04 million shs2.06 million shsTLXTelix Pharmaceuticals$9.70+1.3%$9.93$6.28▼$18.49$3.29B0.08216,466 shs57,991 shsDon't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNLIDenali Therapeutics+3.97%+7.12%-2.47%-13.06%+44.41%RCUSArcus Biosciences+2.96%+6.13%-4.83%+19.33%+167.22%SANASana Biotechnology-0.65%-0.33%-7.29%-26.86%+53.27%TLXTelix Pharmaceuticals+1.06%-5.90%-9.38%+40.94%-42.35%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNLIDenali Therapeutics 2.87Moderate Buy$34.2570.91% UpsideRCUSArcus Biosciences 2.55Moderate Buy$33.8940.03% UpsideSANASana Biotechnology 2.67Moderate Buy$9.50204.00% UpsideTLXTelix Pharmaceuticals 2.78Moderate Buy$21.13117.90% UpsideCurrent Analyst Ratings BreakdownLatest SANA, TLX, DNLI, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.005/14/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$42.00 ➝ $40.005/11/2026RCUSArcus Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$20.00 ➝ $22.005/11/2026DNLIDenali Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$39.005/11/2026SANASana Biotechnology Rodman & RenshawSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.005/8/2026DNLIDenali Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.005/7/2026RCUSArcus Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $34.005/4/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/1/2026SANASana Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNLIDenali TherapeuticsN/AN/AN/AN/A$5.84 per shareN/ARCUSArcus Biosciences$236M12.90N/AN/A$4.17 per share5.80SANASana BiotechnologyN/AN/AN/AN/A$0.43 per shareN/ATLXTelix Pharmaceuticals$803.79M4.09$0.04 per share224.60$1.23 per share7.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)SANASana Biotechnology-$244.17M-$0.93N/AN/AN/AN/A-108.01%-40.68%8/10/2026 (Estimated)TLXTelix Pharmaceuticals-$7.12MN/AN/A57.03N/AN/AN/AN/AN/ALatest SANA, TLX, DNLI, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026SANASana Biotechnology-$0.15-$0.14+$0.01-$0.17N/AN/A5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million3/3/2026Q4 2025SANASana Biotechnology-$0.13-$0.16-$0.03-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDNLIDenali TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ATLXTelix PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNLIDenali Therapeutics0.019.289.28RCUSArcus Biosciences0.194.044.04SANASana BiotechnologyN/A1.291.29TLXTelix Pharmaceuticals1.081.431.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNLIDenali Therapeutics92.92%RCUSArcus Biosciences92.89%SANASana Biotechnology88.23%TLXTelix PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipDNLIDenali Therapeutics12.50%RCUSArcus Biosciences9.60%SANASana Biotechnology25.40%TLXTelix PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableSANASana Biotechnology380278.29 million207.61 millionOptionableTLXTelix Pharmaceuticals1,184339.38 millionN/AN/ASANA, TLX, DNLI, and RCUS HeadlinesRecent News About These CompaniesTelix to Participate in William Blair Growth Stock and Jefferies Global Healthcare ConferencesMay 27 at 7:00 AM | globenewswire.comTelix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's What HappenedMay 24 at 3:51 AM | americanbankingnews.comTelix Pharmaceuticals: PSMA Radiopharmaceutical Player Is Revving UpMay 18, 2026 | seekingalpha.comIPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms DosingMay 18, 2026 | globenewswire.comTelix Pharmaceuticals Ltd ADR TLXMay 17, 2026 | morningstar.comMTelix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment ApproachesMay 15, 2026 | globenewswire.comTelix Issues New Shares to Complete Deferred ImaginAb Acquisition PaymentMay 10, 2026 | theglobeandmail.comMauna Kea Technologies and Telix Pharmaceuticals to Expand Partnership in Uro-oncologic SurgeryMay 8, 2026 | businesswire.comChristian Behrenbruch Acquires 33,435 Shares of Telix Pharmaceuticals (NASDAQ:TLX) StockMay 7, 2026 | insidertrades.comInsider Buying: Telix Pharmaceuticals (NASDAQ:TLX) CEO Buys 33,435 Shares of StockMay 6, 2026 | marketbeat.comTelix Pharmaceuticals (NASDAQ:TLX) CEO Christian Behrenbruch Acquires 34,500 SharesMay 6, 2026 | marketbeat.comNew Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCCMay 4, 2026 | globenewswire.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 - SlideshowMay 2, 2026 | seekingalpha.comInsider Buying: Telix Pharmaceuticals Co-Founder Bought US$997k Of SharesMay 1, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Rating of "Moderate Buy" from AnalystsMay 1, 2026 | marketbeat.comTLX101-Px (Pixlumi®) MAA Accepted in EuropeApril 30, 2026 | globenewswire.comHow TLX597-Tx Phase 2 Dosimetry Data Will Impact Telix Pharmaceuticals (ASX:TLX) InvestorsApril 30, 2026 | finance.yahoo.comTelix Pharmaceuticals Limited (TLX) Discusses Advances in PSMA Therapy and Insights from the OPTIMAL-PSMA Trial with TLX597 TranscriptApril 30, 2026 | seekingalpha.comTelix Pharmaceuticals Webinar Highlights Next-Gen PSMA Therapy, OPTIMAL-PSMA Enrollment Nears EndApril 29, 2026 | marketbeat.comOPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate CancerApril 29, 2026 | globenewswire.comEducational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio ApproachApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSANA, TLX, DNLI, and RCUS Company DescriptionsDenali Therapeutics NASDAQ:DNLI$20.04 +0.66 (+3.41%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Arcus Biosciences NYSE:RCUS$24.20 +0.07 (+0.29%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Sana Biotechnology NASDAQ:SANA$3.12 +0.08 (+2.46%) As of 02:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Telix Pharmaceuticals NASDAQ:TLX$9.70 +0.13 (+1.31%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Micron’s $1 Trillion Memory Melt-Up Keysight: The AI and Defense Stock Seeing Big Price Target Boosts Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
